MCID: HRT032
MIFTS: 75

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 15 17
Congenital Heart Disease 12 29 54 6 15 17 71
Heart Failure 54 6 42 62 17 71 32
Congenital Heart Defects 12 29 6 42 3 62
Heart Diseases 54 42 43 15 71
Congenital Heart Defect 12 6
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 39
Congenital Heart Disorder 74
Heart Defects, Congenital 43
Heart Disease, Congenital 39
Congestive Heart Failure 71
Heart Defects Congenital 54
Heart-Congenital Defect 12
Heart Malformation 12
Heart Defects 15
Heart Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:114 DOID:1682
ICD9CM 34 429.9 746.9
NCIt 49 C3079 C34666
SNOMED-CT 67 13213009 56265001
UMLS 71 C0018798 C0018799 C0018801 more

Summaries for Heart Disease

MedlinePlus : 42 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to heart valve disease and coronary artery anomaly, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are MicroRNAs in cancer and Cardiac Progenitor Differentiation. The drugs Citalopram and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney.

CDC : 3 Congenital heart defects (CHDs) are conditions that are present at birth and can affect the structure of a baby's heart and the way it works. They are the most common type of birth defect. As medical care and treatment have advanced, infants with congenital heart defects are living longer and healthier lives. Many now are living into adulthood.

PubMed Health : 62 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 74 A congenital heart defect (CHD), also known as a congenital heart anomaly and congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2716)
# Related Disease Score Top Affiliating Genes
1 heart valve disease 34.7 NKX2-5 MYH6 MIR21 GATA4
2 coronary artery anomaly 34.2 NKX2-5 MYH6 MIR21 GATA4
3 aortic valve disease 1 33.6 NKX2-5 MYH6 MIR21 H19 GATA4
4 patent ductus arteriosus 1 33.5 NKX2-5 MYH6 GATA4
5 hypoplastic left heart syndrome 33.3 NKX2-5 MYH6 GATA4
6 holt-oram syndrome 33.1 NKX2-5 MYH6 GATA4
7 heart septal defect 32.9 NKX2-5 MYH6 GATA4
8 aortic valve disease 2 32.9 NKX2-5 MYH6 MIR21 GATA4
9 tricuspid atresia 32.8 NKX2-5 GATA4
10 atrial standstill 1 32.7 MYH6 MIR320A GATA4
11 atrioventricular block 32.6 NKX2-5 MHRT GATA4
12 eisenmenger syndrome 32.6 NKX2-5 GATA4
13 atrial heart septal defect 32.5 NKX2-5 MYH6 GATA4
14 atrioventricular septal defect 32.2 NKX2-5 MYH6 GATA4
15 left ventricular noncompaction 32.1 NKX2-5 MYH6 MHRT GATA4
16 ebstein anomaly 32.0 NKX2-5 MYH6 GATA4
17 patent foramen ovale 31.9 NKX2-5 MYH6 GATA4
18 heart, malformation of 30.9 NKX2-5 MYH6
19 intrinsic cardiomyopathy 30.9 NKX2-5 MYH6 MIR21 GATA4
20 dermatomyositis 30.8 MIR214 MIR210 MIR21
21 polymyositis 30.7 MIR214 MIR210 MIR21
22 leukemia, acute myeloid 30.2 MIR320A MIR23A MIR210 MIR21 MIR195 HOTAIR
23 inclusion body myositis 30.2 MIR214 MIR21 BACE1-AS
24 clear cell renal cell carcinoma 30.2 MIR494 MIR320A MIR210 MIR21
25 intestinal disease 30.2 MIR23A MIR214 MIR21 MIR195
26 adrenocortical carcinoma, hereditary 30.2 MIR214 MIR195 H19
27 central nervous system disease 30.1 MIR23A MIR214 MIR21 H19
28 kidney cancer 30.1 MIR214 MIR210 MIR21 HOTAIR H19
29 diffuse large b-cell lymphoma 30.0 MIR320A MIR210 MIR21 HOTAIR
30 atrial septal defect 4 30.0 NKX2-5 H19
31 gastrointestinal system disease 30.0 MIR23A MIR214 MIR21 MIR195
32 large intestine cancer 29.9 MIR23A MIR214 MIR21 MIR195
33 ovarian cancer 29.9 MIR494 MIR214 MIR210 MIR21 MIR195 HOTAIR
34 gastrointestinal system cancer 29.8 MIR23A MIR214 MIR21 MIR195 HOTAIR H19
35 renal cell carcinoma, nonpapillary 29.6 MIR23A MIR210 MIR21 MIR195 HOTAIR H19
36 coronary heart disease 1 12.8
37 deafness, congenital heart defects, and posterior embryotoxon 12.7
38 short stature, developmental delay, and congenital heart defects 12.7
39 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.7
40 congenital heart defects, multiple types, 3 12.7
41 congenital heart defects, multiple types, 4 12.7
42 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.7
43 congenital heart defects and ectodermal dysplasia 12.6
44 hypertensive heart disease 12.6
45 rheumatic heart disease 12.5
46 coronary heart disease 5 12.5
47 coronary heart disease 6 12.5
48 coronary heart disease 7 12.5
49 pulmonary arterial hypertension associated with congenital heart disease 12.4
50 kyphoscoliotic heart disease 12.4

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 309)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

Drugs & Therapeutics for Heart Disease

PubMed Health treatment related to Heart Disease: 62

Although many children who have congenital heart defects don't need treatment , some do. Doctors repair congenital heart defects with catheter procedures or surgery . Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects. The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health. Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Pancrelipase Approved, Investigational Phase 4 53608-75-6
3
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
4
Etanercept Approved, Investigational Phase 4 185243-69-0
5
Infliximab Approved Phase 4 170277-31-3
6
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
7
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Tenecteplase Approved Phase 4 191588-94-0
10
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
11 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
12
Zopiclone Approved Phase 4 43200-80-2 5735
13
Tirofiban Approved Phase 4 144494-65-5 60947
14
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
15
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
16
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
17
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
18
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
19
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
20
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
21
Polyestradiol phosphate Approved Phase 4 28014-46-2
22
Deferiprone Approved Phase 4 30652-11-0 2972
23
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
24
Vancomycin Approved Phase 4 1404-90-6 441141 14969
25
Glyburide Approved Phase 4 10238-21-8 3488
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
28
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
29
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
30
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
31
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
34
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
35
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
36
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
37
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
38
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
39
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
40
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
41
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
42
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
43
Fenofibrate Approved Phase 4 49562-28-9 3339
44
Ticagrelor Approved Phase 4 274693-27-5 9871419
45
Doxazosin Approved Phase 4 74191-85-8 3157
46
Trandolapril Approved Phase 4 87679-37-6 5484727
47
Manidipine Approved, Investigational Phase 4 89226-50-6
48
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
49
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
50
Propranolol Approved, Investigational Phase 4 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
2 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
3 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
4 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
5 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
6 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
7 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
8 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
9 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
10 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
11 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
12 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
13 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
14 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Undergoing Cardiac Surgical Repair. Unknown status NCT00350441 Phase 4 Sildenafil Citrate
15 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
16 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
17 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
18 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
19 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
20 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
21 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
22 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
23 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
24 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
25 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
26 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
27 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
28 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
29 A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus Unknown status NCT03159559 Phase 4 Lipo-PGE1
30 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
31 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
32 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
33 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
34 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
35 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
36 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
37 Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure Unknown status NCT03255044 Phase 4 Atorvastatin;Rosuvastatin
38 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
39 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
40 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
41 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
42 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
43 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
44 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
45 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
46 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
47 Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy Unknown status NCT03380520 Phase 4 Ferric Carboxymaltose;Placebo
48 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
49 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
50 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 29
2 Congenital Heart Defects 29

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

40
Heart, Testes, Kidney, Endothelial, Lung, Brain, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 62090)
# Title Authors PMID Year
1
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. 61 42
31535829 2019
2
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. 61 42
31475794 2019
3
Effects of Serelaxin in Patients with Acute Heart Failure. 61 42
31433919 2019
4
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. 61 46
20837903 2010
5
Imaging Early Postoperative Complications of Cardiothoracic Surgery. 42
31731897 2020
6
Approach to Abnormal Chest Computed Tomography Contrast Enhancement in the Hospitalized Patient. 42
31731905 2020
7
Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. 42
31623840 2019
8
Imaging of Pulmonary Atresia With Ventricular Septal Defect. 42
31738213 2019
9
Cardiac magnetic resonance imaging: the future is bright. 42
31543951 2019
10
Chromosomal Aberrations with Endocrine Relevance (Turner Syndrome, Klinefelter Syndrome, Prader-Willi Syndrome). 42
31588543 2019
11
MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. 46
20837890 2010
12
Effects of myosin heavy chain manipulation in experimental heart failure. 54 61
19854200 2010
13
Myostatin: an overlooked player in heart failure? 54 61
20348549 2010
14
Heart failure and pulmonary hypertension. 54 61
20347789 2010
15
Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. 54 61
20211335 2010
16
[Novel GATA4 mutations identified in patients with congenital heart disease]. 54 61
20450724 2010
17
Novel treatment strategy with direct renin inhibition against heart failure. 54 61
20228725 2010
18
Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? 54 61
20156936 2010
19
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. 54 61
20233990 2010
20
NKX2.5 mutations in patients with non-syndromic congenital heart disease. 54 61
19073351 2010
21
[Polymorphism of eNOS and iNOS Genes and Chronic Heart Failure in Patients With Ischemic Heart Disease]. 54 61
20459417 2010
22
Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. 54 61
19945058 2010
23
Endogenous erythropoietin and outcome in heart failure. 54 61
20048213 2010
24
Phosphodiesterase inhibition in heart failure. 54 61
19096931 2009
25
Beta-adrenergic blockers for chronic heart failure. 54 61
19829179 2009
26
ST2 and adrenomedullin in heart failure. 54 61
19631176 2009
27
Growth-differentiation factor-15 in heart failure. 54 61
19631178 2009
28
Newer biomarkers in heart failure. 54 61
19631181 2009
29
Plasma urocortin 1 in human heart failure. 54 61
19808377 2009
30
Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. 46
19514064 2009
31
Cystatin C in acute heart failure without advanced renal impairment. 54 61
19393984 2009
32
Can adiponectin be a novel metabolic biomarker for heart failure? 54 61
19465781 2009
33
MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. 46
19380620 2009
34
The role of IL-1 in the pathogenesis of heart disease. 54 61
19479203 2009
35
Plasma atrial natriuretic peptide in healthy calves and calves with congenital heart disease. 54 61
19658257 2009
36
Recent insights on chronic heart failure, cachexia and nutrition. 54 61
19363338 2009
37
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 54 61
19377497 2009
38
Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease. 54 61
19258379 2009
39
[The mechanism of TBX5 abnormal expression in simple congenital heart disease]. 54 61
19586889 2009
40
Is erythropoietin behind maladaptive anemic heart failure? 54 61
19168730 2009
41
GATA4 and NKX2.5 gene analysis in Chinese Uygur patients with congenital heart disease. 54 61
19302747 2009
42
Energy metabolism in heart failure and remodelling. 54 61
18987051 2009
43
[Erythropoietin in patients with chronic heart failure]. 54 61
19469252 2009
44
Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). 54 61
19165564 2009
45
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. 46
19043405 2008
46
[Heart hypertrophy and heart failure--experimental findings for arrhythmogenesis]. 54 61
19085808 2008
47
Uric acid, xanthine oxidase and heart failure: unresolved issues. 54 61
19010082 2008
48
Anemia in heart failure: to treat or not to treat? 54 61
19026176 2008
49
GATA4 mutations in 486 Chinese patients with congenital heart disease. 54 61
18672102 2008
50
Erythropoietin, haemoglobin, heart failure, and mortality. 54 61
18786914 2008

Variations for Heart Disease

ClinVar genetic disease variations for Heart Disease:

6 (show top 50) (show all 61) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NKX2-5 NM_004387.4(NKX2-5):c.443C>A (p.Ala148Glu)SNV Pathogenic 219169 rs864321649 5:172660104-172660104 5:173233101-173233101
2 NKX2-5 NM_004387.4(NKX2-5):c.391G>A (p.Glu131Lys)SNV Pathogenic 219168 rs864321648 5:172660156-172660156 5:173233153-173233153
3 NKX2-5 NM_004387.4(NKX2-5):c.335-1G>TSNV Pathogenic 219165 rs864321645 5:172660213-172660213 5:173233210-173233210
4 NKX2-5 NM_004387.4(NKX2-5):c.182C>G (p.Ala61Gly)SNV Pathogenic 219170 rs864321650 5:172661905-172661905 5:173234902-173234902
5 GATA4 NM_002052.5(GATA4):c.23C>A (p.Ala8Asp)SNV Pathogenic 219226 rs864321698 8:11565844-11565844 8:11708335-11708335
6 GATA4 NM_002052.5(GATA4):c.25G>A (p.Ala9Thr)SNV Pathogenic 219227 rs864321699 8:11565846-11565846 8:11708337-11708337
7 GATA4 NM_002052.5(GATA4):c.27C>A (p.Ala9=)SNV Pathogenic 219231 rs864321703 8:11565848-11565848 8:11708339-11708339
8 GATA4 NM_002052.5(GATA4):c.383A>T (p.Glu128Val)SNV Pathogenic 219228 rs864321700 8:11566204-11566204 8:11708695-11708695
9 GATA4 NM_002052.5(GATA4):c.397A>T (p.Ser133Cys)SNV Pathogenic 219229 rs864321701 8:11566218-11566218 8:11708709-11708709
10 GATA4 NM_002052.5(GATA4):c.682T>A (p.Trp228Arg)SNV Pathogenic 219230 rs864321702 8:11606493-11606493 8:11748984-11748984
11 GATA4 NM_002052.5(GATA4):c.997+2T>GSNV Pathogenic 219233 rs864321705 8:11612644-11612644 8:11755135-11755135
12 GATA4 NM_002052.5(GATA4):c.1263C>T (p.Ser421=)SNV Pathogenic 219232 rs864321704 8:11615918-11615918 8:11758409-11758409
13 ABL1 NM_005157.6(ABL1):c.1009G>A (p.Ala337Thr)SNV Pathogenic 374794 rs1060499548 9:133748348-133748348 9:130872961-130872961
14 ABL1 NM_005157.6(ABL1):c.677A>G (p.Tyr226Cys)SNV Pathogenic 374795 rs1060499547 9:133738277-133738277 9:130862890-130862890
15 GATA4 NM_002052.5(GATA4):c.910-55T>CSNV Pathogenic 433018 rs1554498312 8:11612500-11612500 8:11754991-11754991
16 GATA4 NM_002052.5(GATA4):c.997+103G>TSNV Pathogenic 433019 rs113049875 8:11612745-11612745 8:11755236-11755236
17 GATA4 NM_002052.5(GATA4):c.998-26G>ASNV Pathogenic 433021 rs1554498708 8:11614418-11614418 8:11756909-11756909
18 GATA4 NM_002052.5(GATA4):c.*1168T>CSNV Pathogenic 433025 rs549543886 8:11617152-11617152 8:11759643-11759643
19 MYH6 NM_002471.3(MYH6):c.1410+1G>ASNV Pathogenic 561059 rs1566513862 14:23869917-23869917 14:23400708-23400708
20 TBX5 NM_080717.3(TBX5):c.835_837delinsAC (p.Glu279fs)indel Likely pathogenic 495731 rs1555223294 12:114793907-114793909 12:114356102-114356104
21 TBX5 NM_080717.3(TBX5):c.835_837delinsAG (p.Glu279fs)indel Likely pathogenic 495732 rs1555223294 12:114793907-114793909 12:114356102-114356104
22 NOTCH1 NM_017617.5(NOTCH1):c.1810del (p.Ile604fs)deletion Likely pathogenic 692037 9:139410028-139410028 9:136515576-136515576
23 DMD NM_004006.2(DMD):c.8083C>T (p.Pro2695Ser)SNV Conflicting interpretations of pathogenicity 497501 rs755445214 X:31645924-31645924 X:31627807-31627807
24 AKAP9 NM_005751.4(AKAP9):c.7208A>G (p.Glu2403Gly)SNV Conflicting interpretations of pathogenicity 519379 rs150102469 7:91708655-91708655 7:92079341-92079341
25 CERS1 , GDF1 NM_001492.6(GDF1):c.1091T>C (p.Met364Thr)SNV Conflicting interpretations of pathogenicity 522571 rs374016704 19:18979434-18979434 19:18868625-18868625
26 MYOT NM_006790.2(MYOT):c.398C>T (p.Pro133Leu)SNV Conflicting interpretations of pathogenicity 533010 rs779568205 5:137211559-137211559 5:137875870-137875870
27 GATA4 NM_002052.5(GATA4):c.*1256A>TSNV Conflicting interpretations of pathogenicity 433026 rs12458 8:11617240-11617240 8:11759731-11759731
28 RBM20 NM_001134363.3(RBM20):c.3169C>T (p.Arg1057Trp)SNV Conflicting interpretations of pathogenicity 470608 rs199830512 10:112581546-112581546 10:110821788-110821788
29 GATA4 NM_002052.5(GATA4):c.1146+129C>TSNV Conflicting interpretations of pathogenicity 433022 rs116052854 8:11614721-11614721 8:11757212-11757212
30 GATA4 NM_002052.5(GATA4):c.1146+177C>TSNV Conflicting interpretations of pathogenicity 433023 rs12156163 8:11614769-11614769 8:11757260-11757260
31 GATA4 NM_002052.5(GATA4):c.1147-107A>GSNV Conflicting interpretations of pathogenicity 433015 rs745379 8:11615695-11615695 8:11758186-11758186
32 GATA4 NM_002052.5(GATA4):c.*852G>ASNV Conflicting interpretations of pathogenicity 433024 rs804290 8:11616836-11616836 8:11759327-11759327
33 GATA4 NM_002052.5(GATA4):c.997+200G>ASNV Conflicting interpretations of pathogenicity 433020 rs3729851 8:11612842-11612842 8:11755333-11755333
34 TTN NM_001267550.2(TTN):c.5479G>T (p.Ala1827Ser)SNV Conflicting interpretations of pathogenicity 47184 rs141213991 2:179641112-179641112 2:178776385-178776385
35 GATA4 NM_002052.5(GATA4):c.617-116T>CSNV Conflicting interpretations of pathogenicity 433016 rs3735819 8:11606312-11606312 8:11748803-11748803
36 GATA4 NM_002052.5(GATA4):c.617-64G>CSNV Conflicting interpretations of pathogenicity 433017 rs10503425 8:11606364-11606364 8:11748855-11748855
37 NOTCH1 NM_017617.5(NOTCH1):c.4168C>A (p.Pro1390Thr)SNV Conflicting interpretations of pathogenicity